Domain Therapeutics

Domain Therapeutics is a clinical-stage global biopharmaceutical company founded in 2001, headquartered in France. The company is focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), which are crucial in drug discovery. Domain Therapeutics aims to unlock new possibilities in cancer by approaching it differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. With two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, the company has established itself as a leader in GPCRs in immuno-oncology. The company's proprietary programs, including DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, DT-9081, an EP4 receptor antagonist, and M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA, demonstrate its commitment to delivering innovative immunotherapies to patients. Domain Therapeutics also maintains an optimized pipeline of best-in-class and first-in-class GPCR targets selected through its proprietary cross-validation drug discovery and development platform. The company recently received a €10.00M grant investment on 25 January 2024 from Agence National de la Recherche, further affirming its position in the biotechnology, healthcare, and pharmaceutical industries. With its focused approach and solid partnerships, Domain Therapeutics is poised to make significant contributions to the field of cancer immunotherapy.